Federal Circuit ruling keeps Amgen's Eylea biosimilar on the market
The US Court of Appeals for the Federal Circuit on Friday ruled against Regeneron in a closely-watched patent infringement case involving the New York biotech's blockbuster eye drug Eylea and Amgen's competing biosimilar Pavblu, which ...
The US Court of Appeals for the Federal Circuit on Friday ruled against Regeneron in a closely-watched patent infringement case involving the New York biotech's blockbuster eye drug Eylea and Amgen's competing biosimilar Pavblu, which ...
